Information de reference pour ce titreAccession Number: | 00001716-200604080-00022.
|
Author: | VENERITO, M. *,1; TREIBER, G. *,1; WEX, T. *; KUESTER, D. +; ROESSNER, A. +; DI MARIO, F. ++; MALFERTHEINER, P. *
|
Institution: | (*)Department of Gastroenterology, Hepatology and Infectious Diseases +Institute of Pathology, Otto-von-Guericke University, Magdeburg, Germany ++Department of Clinical Sciences, Chair of Gastroenterology, University of Parma, Parma, Italy
|
Title: | |
Source: | Alimentary Pharmacology & Therapeutics. 23(8):1225-1233, April 2006.
|
Abstract: | Background: The mechanisms by which Helicobacter pylori and low-dose aspirin induce gastric damage are not completely elucidated.
Aim: To evaluate the effects of low-dose aspirin on gastric damage, mucosal prostaglandin-E2 levels and cyclooxygenase-enzyme expression in relation to the H. pylori status.
Methods: Twenty healthy volunteers (H. pylori positive, n = 10; H. pylori negative, n = 10) received aspirin 100 mg/die for 1 week. At days 0, 1, 3 and 7, gastric mucosal lesions were studied by oesophagogastroduodenoscopy and histology. COX-1 and COX-2 were determined by immunohistochemistry and reverse-transcriptase polymerase chain reaction, and mucosal prostaglandin-E2 levels by enzyme-linked immunosorbent assay. Nine H. pylori-positive subjects repeated the protocol after H. pylori eradication.
Results: All groups developed a similar number of erosions. COX-1 and COX-2 expression, as well as mucosal prostaglandin-E2 levels were not influenced by H. pylori status and aspirin medication. Helicobacter pylori-negative and H. pylori-eradicated subjects who developed aspirin-induced erosions had significant lower pre-treatment antral prostaglandin-E2 levels than those without erosions (3.6 ng/[mu]g vs. 6.3 ng/[mu]g protein and 3.6 ng/[mu]g vs. 6.0 ng/[mu]g protein, respectively, P < 0.01 Mann-Whitney U-test).
Conclusions: In healthy subjects, low-dose aspirin for 1 week does neither affect cyclooxygenase expression nor mucosal prostaglandin-E2 levels. Antral prostaglandin-E2-basal levels appear to be critical for development of aspirin-induced gastric damage in subjects without H. pylori infection.
Copyright (C) 2006 Blackwell Publishing Ltd.
|
References: | 1 Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004; 19: 9-16.
2 Hoshino T, Tsutsumi S, Tomisato W, Hwang HJ, Tsuchiya T, Mizushima T. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 2003; 278: 12752-8.
3 Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
4 Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49: 443-53.
5 Weissmann G. Aspirin. Sci Am 1991; 264: 84-90.
6 Smith WL, Dewitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82.
7 Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.
8 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
9 Stange EF, Preclik G, Gerber K, et al. Prostaglandin synthesis in stomach and duodenal mucosa of the human: effect of aspirin with and without antacid. Z Gastroenterol 1987; 25: 162-5.
10 Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994; 120: 184-9.
11 Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
12 Romano M, Ricci V, Memoli A, et al. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem 1998; 273: 28560-3.
13 Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114: 245-55.
14 McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1218-23.
15 Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci 2001; 46: 2277-84.
16 Meyer F, Ramanujam KS, Gobert AP, James SP, Wilson KT. Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori. J Immunol 2003; 171: 3913-7.
17 Futagami S, Hiratsuka T, Tatsuguchi A, et al. Monocyte chemoattractant protein 1 (MCP-1) released from Helicobacter pylori stimulated gastric epithelial cells induces cyclooxygenase 2 expression and activation in T cells. Gut 2003; 52: 1257-64.
18 Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000; 47: 762-70.
19 Tatsuguchi A, Sakamoto C, Wada K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000; 46: 782-9.
20 Nardone G, Rocco A, Vaira D, et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H. pylori-related gastric carcinogenesis. J Pathol 2004; 202: 305-12.
21 Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
22 Malfertheiner P, Enrique D, Heckenmuller H, Neubrand M, Fischer HP, Sauerbruch T. Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1996; 8: 53-6.
23 Leodolter A, Dominguez-Munoz JE, von Arnim U, Kahl S, Peitz U, Malfertheiner P. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94: 2100-4.
24 Wex T, Treiber G, Lendeckel U, Malfertheiner P. A two-step method for the extraction of high-quality RNA from endoscopic biopsies. Clin Chem Lab Med 2003; 41: 1033-7.
25 Feldman M, Shewmake K, Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1113-20.
26 Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.
27 Wallace JL, Zamuner SR, McKnight W, et al. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 286: G76-81.
28 Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 2003; 100: 10937-41.
29 Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med 1992; 116: 636-40.
30 Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 748-51.
31 Mertz-Nielsen A, Hillingso J, Frokiaer H, Bukhave K, Rask-Madsen J. Gastric bicarbonate secretion and release of prostaglandin E2 are increased in duodenal ulcer patients but not in Helicobacter pylori-positive healthy subjects. Scand J Gastroenterol 1996; 31: 38-43.
32 Cryer B, Faust TW, Goldschmiedt M, Redfern JS, Lee E, Feldman M. Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationships with demographics, environmental, and histological factors, including Helicobacter pylori. Am J Gastroenterol 1992; 87: 1747-54.
33 Preclik G, Abedin G, Stange EF, Baczako K, Ditschuneit H. Endogenous prostaglandin synthesis and gastritis: lack of correlation with endoscopic findings, Helicobacter colonization and leukocytic infiltration of the mucosa. Z Gastroenterol 1992; 30: 130-3.
34 Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999; 116: 1319-29.
35 Wu CY, Wu MS, Chen CJ, Li MC, Lin JT, Chen GH. The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer. J Clin Gastroenterol 2005; 39: 50-5.
|
Language: | English.
|
Document Type: | Original article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0269-2813
|
NLM Journal Code: | a5d, 8707234
|
Annotation(s) | |
|
|